CEO Alice Zhang Speaks at 2017 Neurotech Investing & Partnering Conference
CEO Alice Zhang speaks about Verge Genomics on "Targeting Orphan Diseases" panel
June 1, 2017
SAN FRANCISCO — Verge Genomics CEO Alice Zhang was invited to speak on a panel featuring industry-leading biotechnology companies focused on orphan disease drug discovery at the annual Neurotech Investing & Partnering Conference. At the panel, Zhang discussed her experience co-founding and leading Verge Genomics and the Company's progress in its lead program in ALS. The panel focused on successful R&D strategies for addressing smaller rare disease markets.
The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. This market-defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.
About Verge Genomics
Verge is a next-generation drug discovery company that is using human genomic data to accelerate the discovery of treatments for neurodegeneration. Founded by scientists from leading neuro-genomics labs, the Verge team is 12 people including 10 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans.